These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 30273552)

  • 1. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():376-401. PubMed ID: 30273552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():359-375. PubMed ID: 30273553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
    Mullane K; Williams M
    Biochem Pharmacol; 2020 Jul; 177():113945. PubMed ID: 32247851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity.
    Mullane K; Williams M
    Curr Protoc Pharmacol; 2019 Mar; 84(1):e57. PubMed ID: 30802363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
    Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroinflammation in pathogenesis of Alzheimer's disease: Phytochemicals as potential therapeutics.
    Vaiserman A; Koliada A; Lushchak O
    Mech Ageing Dev; 2020 Jul; 189():111259. PubMed ID: 32450086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?
    Mullane K; Williams M
    Biochem Pharmacol; 2013 Feb; 85(3):289-305. PubMed ID: 23178653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings.
    Khezri MR; Yousefi K; Mahboubi N; Hodaei D; Ghasemnejad-Berenji M
    Biochem Pharmacol; 2022 Mar; 197():114945. PubMed ID: 35134385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological aspects and anti-amyloid strategy for Alzheimer's dementia.
    Liščić RM
    Arh Hig Rada Toksikol; 2013 Dec; 64(4):603-8. PubMed ID: 24384767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions.
    Ma C; Hong F; Yang S
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-potent Natural Scaffolds Targeting Amyloid Cascade: In Search of Alzheimer's Disease Therapeutics.
    Chakraborty S
    Curr Top Med Chem; 2017; 17(31):3336-3348. PubMed ID: 29345580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.
    Infante-Garcia C; Ramos-Rodriguez JJ; Hierro-Bujalance C; Ortegon E; Pickett E; Jackson R; Hernandez-Pacho F; Spires-Jones T; Garcia-Alloza M
    Mol Neurobiol; 2018 Jul; 55(7):6130-6144. PubMed ID: 29224179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.
    Ceyzériat K; Zilli T; Millet P; Frisoni GB; Garibotto V; Tournier BB
    Curr Alzheimer Res; 2020; 17(2):112-125. PubMed ID: 32129164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.
    Parent MJ; Zimmer ER; Shin M; Kang MS; Fonov VS; Mathieu A; Aliaga A; Kostikov A; Do Carmo S; Dea D; Poirier J; Soucy JP; Gauthier S; Cuello AC; Rosa-Neto P
    J Neurosci; 2017 Dec; 37(50):12263-12271. PubMed ID: 29097597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
    Ising C; Stanley M; Holtzman DM
    Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The amyloid cascade hypothesis: are we poised for success or failure?
    Karran E; De Strooper B
    J Neurochem; 2016 Oct; 139 Suppl 2():237-252. PubMed ID: 27255958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds.
    Hirohata M; Ono K; Yamada M
    Curr Pharm Des; 2008; 14(30):3280-94. PubMed ID: 19075706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.